Top

News & Events

In The News

In The News

PharmaVentures Termsheet

The old pharmaceutical industry business model of the $1bn “Blockbuster” drug is rapidly being supplemented by more personalised approaches to medicine, with reimbursement being matched to effectiveness vs. a trial and error approach. Within this new environment for “Microbusters”, orphan drugs that treat rare diseases, i.e. drugs with small patient populations (in the UK this is defined as less than 200,000 patients) but that can command very high prices (up to £300,000 per patient per year) have become popular.

Read more »

Pharma Television

The importance of communications in Life Sciences, October 2012 - [00:05:45]

Read more »

Nature Biotechnology

BioEntrepreneur: Backing Your Brand, vol. 28, Jan. 2010

Read more »